论文部分内容阅读
目的:观察卡培他滨维持化疗治疗晚期胃癌的效果,以供临床参考。方法:将我院2011年5月至2013年4月收治的晚期胃癌患者98例纳入本研究,根据随机原则分组。对照组接受5-氟尿嘧啶联合顺铂化疗方案,实验组接受在此基础上辅以卡培他滨治疗。3个疗程后,对比两组在临床疗效和毒副反应方面的差异性。结果:与对照组对比,我们发现实验组总有效率明显较高,组间差异经统计学分析后认为有意义(p<0.05)。对比两组毒副反应发生率和Ⅲ级以上严重毒副反应发生率发现,组间差异统计学分析后认为无意义(p>0.05)。结论:卡培他滨维持化疗治疗晚期胃癌具有满意的效果,且不会增加毒副反应的发生率和严重程度,今后可将其作为晚期胃癌化疗的有效方案推广应用。
Objective: To observe the effect of capecitabine in maintaining chemotherapy for advanced gastric cancer for clinical reference. Methods: A total of 98 patients with advanced gastric cancer admitted to our hospital from May 2011 to April 2013 were included in this study and grouped according to the principle of randomization. The control group received 5-fluorouracil plus cisplatin chemotherapy regimen, and the experimental group received capecitabine on this basis. After 3 courses, compared the two groups in the clinical efficacy and toxicity differences. Results: Compared with the control group, we found that the total effective rate was significantly higher in the experimental group, and the difference between the groups was considered statistically significant (p <0.05). Comparing the incidence of toxic and side effects in both groups and the incidence of serious grade Ⅲ or higher toxicity, we found no significant difference between groups (p> 0.05). CONCLUSION: Capecitabine maintains satisfactory efficacy in the treatment of advanced gastric cancer and does not increase the incidence and severity of toxic reactions. Therefore, capecitabine can be used as an effective regimen for advanced gastric cancer chemotherapy.